These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11747043)

  • 1. Discounting for health effects in cost-benefit and cost-effectiveness analysis.
    Gravelle H; Smith D
    Health Econ; 2001 Oct; 10(7):587-99. PubMed ID: 11747043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discounting costs and effects: a reconsideration.
    van Hout BA
    Health Econ; 1998 Nov; 7(7):581-94. PubMed ID: 9845252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
    Dolan P; Edlin R
    J Health Econ; 2002 Sep; 21(5):827-43. PubMed ID: 12349884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double discounting of QALYs.
    MacKeigan LD; Gafni A; O'Brien BJ
    Health Econ; 2003 Feb; 12(2):165-9. PubMed ID: 12563665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes.
    Donaldson C; Birch S; Gafni A
    Health Econ; 2002 Jan; 11(1):55-70. PubMed ID: 11788982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
    Tavakoli M; Malek M
    J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention, policy, and paradox: what is the value of future health?
    Ganiats TG
    Am J Prev Med; 1997; 13(1):12-7. PubMed ID: 9037337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 'fair innings argument' deserves a fairer hearing! Comments by Alan Williams on Nord and Johannesson.
    Williams A
    Health Econ; 2001 Oct; 10(7):583-5. PubMed ID: 11747042
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards a healthier discount procedure.
    Klock RM; Brouwer WB; Annemans LJ; Bos JM; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2005 Feb; 5(1):59-63. PubMed ID: 19807560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discounting in the economic evaluation of health care interventions.
    Krahn M; Gafni A
    Med Care; 1993 May; 31(5):403-18. PubMed ID: 8501989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring the social importance of concentration or dispersion of individual health benefits.
    Rodríguez-Míguez E; Pinto-Prades JL
    Health Econ; 2002 Jan; 11(1):43-53. PubMed ID: 11788981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.
    Caro JJ; Ward A; Deniz HB; O'Brien JA; Ehreth JL
    Value Health; 2007; 10(1):13-22. PubMed ID: 17261112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications.
    Basu A
    J Health Econ; 2020 Mar; 70():102287. PubMed ID: 31972535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.
    Meltzer D; Egleston B; Stoffel D; Dasbach E
    Med Care; 2000 Jun; 38(6):679-85. PubMed ID: 10843315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical arguments for the discounting of health consequences: where do we go from here?
    Lazaro A
    Pharmacoeconomics; 2002; 20(14):943-61. PubMed ID: 12403636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.
    Brennan A; Akehurst R; Davis S; Sakai H; Abbott V
    Value Health; 2007; 10(1):32-41. PubMed ID: 17261114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Counting and discounting gained life-years.
    Søgaard J; Gyrd-Hansen D
    Dev Health Econ Public Policy; 1998; 6():51-74. PubMed ID: 10662409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.